相关实验视频

Updated: Jul 25, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

一个连续的队列研究评估单剂KappaMab和KappaMab结合莱纳利多米德和低剂量德克萨在复发和/或耐火的卡帕轻链受限多发性骨髓瘤 (AMaRC 01-16) 中

Andrew Spencer¹, Anna Kalff¹, Jake Shortt^2,3

¹Department of Clinical Haematology, Alfred Health-Monash University, Melbourne, Victoria, Australia.

British journal of haematology

|June 26, 2023

概括

KappaMab (KM) 结合莱纳利多米德和德克萨美 (Rd) 显示,在复发性耐火性卡帕受限多发性髓瘤 (κMM) 中,响应率为82.5%. 这种组合疗法显示出显著的疗效和有利的安全性.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
血液学血液学血液学

背景情况:

卡帕髓瘤抗原 (KMA) 在卡帕受限多发性髓瘤 (κMM) 的恶性血细胞上表达.
之前的研究证实KappaMab (KM) 具有良好的毒性概况和抗髓瘤活性.
活体研究表明,列纳利多米德可调节KMA并增强效应细胞细胞毒性.

研究的目的:

评估KM与列纳利多米德和德克萨米他松 (KM-Rd) 结合的疗效和安全性,用于复发性,耐火性 κMM 患者.
将KM-Rd的结果与接受莱纳利多米德和甲 (Rd) 的现实世界队列进行比较.

主要方法:

一项IIb期研究,对复发性,耐火 κMM患者给予KM或KM-Rd.
与来自澳大利亚和新西兰骨髓瘤和相关疾病登记处 (MRDR) 的匹配病例控制队列进行比较,他们接受了Rd.
评估整体反应率 (ORR) 和安全概况.

主要成果:

KM-Rd的ORR为82.5%,明显高于Rd-MRDR队列的45.1%的ORR.
单剂KM和KM-Rd两种疗法都耐受得很好.
在其他临床环境中,KM-Rd的安全概况与仅接受Rd的患者相似.

结论:

在复发性,耐火 κMM.中,KM-Rd 显示出显著的疗效和出色的安全性.
进一步的临床试验是有必要的,以探索升级的KM剂量和与其他标准护理治疗的组合.

关键词:

卡帕玛巴姆巴姆 (KappaMabMab) 是一个卡帕骨髓瘤抗原是一种抗原.莱纳利多胺的使用方法一个单克隆抗体.多发性骨髓瘤是多发性骨髓瘤的一种.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...